Article info

2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19
Free

Authors

  • Alessia Alunno Internal Medicine and Nephrology Unit, Department of Life, Health & Environmental Sciences, University of L'Aquila, L'Aquila, Italy PubMed articlesGoogle scholar articles
  • Aurélie Najm Institute of Infection, Immunity and Inflammation, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, UK PubMed articlesGoogle scholar articles
  • Pedro M Machado Centre for Rheumatology and Department of Neuromuscular Diseases, University College London, London, UKNational Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre (BRC), University College London Hospitals NHS Foundation Trust, London, UKDepartment of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, London, UK PubMed articlesGoogle scholar articles
  • Heidi Bertheussen Patient Research Partner, EULAR, Oslo, Norway PubMed articlesGoogle scholar articles
  • Gerd-Rüdiger R Burmester Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Freie Universität und Humboldt-Universität Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Francesco Carubbi Internal Medicine and Nephrology Unit, Department of Life, Health & Environmental Sciences, University of L'Aquila, L'Aquila, Italy PubMed articlesGoogle scholar articles
  • Gabriele De Marco Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & The NIHR Leeds Biomedical Research Centre, Chapel Allerton Hospital, Leeds, UK PubMed articlesGoogle scholar articles
  • Roberto Giacomelli Rheumatology and Clinical Immunology Unit, University of Rome "Campus Biomedico" School of Medicine, Rome, Italy PubMed articlesGoogle scholar articles
  • Olivier Hermine Department of Hematology, Hôpital Necker, Assistance Publique - Hôpitaux de Paris, Paris, FranceInstitut Imagine, Université de Paris, INSERM UMR1183, Paris, France PubMed articlesGoogle scholar articles
  • John D Isaacs Translational and Clinical Research Institute, Newcastle University and Musculoskeletal Unit, Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK PubMed articlesGoogle scholar articles
  • Isabelle Koné-Paut Department of Paediatric Rheumatology, Reference Centre for Autoinflammatory Diseases and Amyloidosis (CEREMAIA), Bicêtre University Hospital, AP-HP, Le Kremlin-Bicetre, FranceUniversity of Paris Sud Saclay, Paris, France PubMed articlesGoogle scholar articles
  • César Magro-Checa Department of Rheumatology, Zuyderland Medical Centre Heerlen, Heerlen, Netherlands PubMed articlesGoogle scholar articles
  • Iain B McInnes Institute of Infection, Immunity and Inflammation, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, UK PubMed articlesGoogle scholar articles
  • Pier Luigi Meroni Experimental Laboratory of Immunological and Rheumatologic Researches, Istituto Auxologico Italiano IRCCS, Milano, Italy PubMed articlesGoogle scholar articles
  • Luca Quartuccio Department of Medicine, Rheumatology Clinic, University of Udine, ASUFC Udine, Udine, Italy PubMed articlesGoogle scholar articles
  • A V Ramanan University Hospitals Bristol NHS Foundations Trust, Bristol, UKTranslational Health Sciences, University of Bristol, Bristol, UK PubMed articlesGoogle scholar articles
  • Manuel Ramos-Casals Department of Autoimmune Diseases, ICMiD, Laboratory of Autoimmune Diseases Josep Font, IDIBAPS-CELLEX, Department of Autoimmune Diseases, ICMiD, University of Barcelona, Hospital Clínic, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Javier Rodríguez Carrio Department of Functional Biology, Immunology Area, Faculty of Medicine, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), University of Oviedo, Oviedo, Spain PubMed articlesGoogle scholar articles
  • Hendrik Schulze-Koops Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, Ludwig-Maximilians University Munich, Munich, Germany PubMed articlesGoogle scholar articles
  • Tanja A Stamm Section for Outcomes Research, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna and Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Wien, Austria PubMed articlesGoogle scholar articles
  • Sander W Tas Department of Rheumatology and Clinical Immunology, Amsterdam Rheumatology and immunology Center, Amsterdam University Medical Centres, AMC/University of Amsterdam, Amsterdam, Netherlands PubMed articlesGoogle scholar articles
  • Benjamin Terrier Department of Internal Medicine, Cochin University Hospital, Paris, France; National Referral Centre for Systemic and Autoimmune Diseases, University Paris Descartes, Sorbonne Paris Cité, Paris, France PubMed articlesGoogle scholar articles
  • Dennis G McGonagle Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & The NIHR Leeds Biomedical Research Centre, Chapel Allerton Hospital, Leeds, UK PubMed articlesGoogle scholar articles
  • Xavier Mariette Department of Rheumatology, INSERM UMR1184, Le Kremlin Bicêtre, FranceDepartment of Rheumatology, Université Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, INSERM UMR1184, Le Kremlin Bicêtre, France PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Xavier Mariette, Department of Rheumatology, INSERM UMR1184, Le Kremlin Bicêtre, France; xavier.mariette{at}aphp.fr
View Full Text

Citation

Alunno A, Najm A, Machado PM, et al
2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19

Publication history

  • Received August 16, 2021
  • Accepted September 29, 2021
  • First published October 7, 2021.
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.